BPC-157: The Complete Research Guide
A comprehensive overview of BPC-157 — mechanism of action, research findings, protocols, and how it compares to TB-500 for tissue repair.
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found in gastric juice. It has accumulated one of the most extensive preclinical research profiles of any synthetic peptide, spanning tendon repair, gut healing, neurological protection, and systemic anti-inflammatory effects.
What Is BPC-157?
BPC-157 is a partial sequence of the body protection compound originally isolated from human gastric juice. The “157” refers to its position in the parent protein. The full sequence is: GEPPPGKPADDAGLV.
It is not found naturally in this exact form in the body — it is a synthetic fragment that has been engineered for stability and tested extensively in animal models.
Mechanism of Action
BPC-157 operates through several parallel pathways:
Growth Factor Upregulation
BPC-157 significantly upregulates VEGF (vascular endothelial growth factor), promoting angiogenesis — the formation of new blood vessels. This is central to its healing properties, as vascularisation is rate-limiting in tendon and ligament repair.
It also upregulates EGF (epidermal growth factor), promoting proliferation of fibroblasts and epithelial cells critical for tissue regeneration.
Nitric Oxide System
BPC-157 modulates the nitric oxide (NO) system, promoting eNOS (endothelial NOS) activity. This produces vasodilatory effects that improve local blood flow to injured tissue and contributes to its anti-inflammatory profile.
Tendon-to-Bone Interface
A particularly studied mechanism involves BPC-157 increasing the expression of tendon-related growth factors at the enthesis (tendon-bone junction), the site of chronic sports injuries like Achilles tendinopathy and patellar tendinopathy.
Gut Protection
The peptide inhibits COX-2 pathways and modulates growth hormone receptor expression in intestinal tissue. This is the likely mechanism behind its consistently observed gastroprotective effects in models of NSAID-induced gastric ulcers, inflammatory bowel disease, and intestinal fistulas.
Key Research Areas
Tendon and Ligament Repair
Multiple rodent studies demonstrate significantly accelerated healing of Achilles tendon transection with BPC-157 compared to controls. A 2010 study in the Journal of Applied Physiology found that systemic (intraperitoneal) BPC-157 administration produced superior functional recovery at 4 weeks post-transection versus saline controls.
Cruciate ligament and rotator cuff models show similar results: faster fibroblast proliferation, improved tensile strength of healing tissue, and reduced scar tissue formation.
Inflammatory Bowel Disease
This is arguably the most robust research area for BPC-157. Models of TNBS-induced colitis (an established rodent model of IBD) consistently show:
- Reduced mucosal inflammation scores
- Faster epithelial regeneration
- Decreased TNF-α and IL-6 at the lesion site
Neurological Applications
A growing body of preclinical data suggests BPC-157 has neuroprotective and potentially nootropic properties:
- Improved recovery from traumatic brain injury models
- Neuroprotection in models of Parkinson’s disease (MPTP-induced nigral neuron loss)
- Anxiolytic effects in elevated plus maze studies
- Reversal of certain corticosteroid-induced cognitive deficits
The proposed mechanism involves dopaminergic and GABAergic modulation, as well as VEGF-driven neuroangiogenesis.
BPC-157 vs. TB-500
These two peptides are frequently compared and often stacked. Understanding the distinction is important for research design.
| Parameter | BPC-157 | TB-500 (Thymosin β4) |
|---|---|---|
| Source | Gastric juice protein | Ubiquitous cellular protein |
| Primary mechanism | VEGF/EGF, NO, COX-2 | Actin sequestration, VEGF |
| Strongest evidence | Tendons, gut, ligaments | Cardiac muscle, skin wounds |
| Administration | SC local or systemic; oral | SC systemic |
| Half-life | ~4h (estimated) | ~24-36h |
| Oral activity | Yes (some evidence) | No |
The key practical distinction: BPC-157 appears more effective for local tendon/ligament injuries and GI issues; TB-500 shows stronger systemic effects and cardiac tissue studies. Many researchers use both in parallel for maximum coverage of healing pathways.
Research Protocol Context
In the majority of preclinical studies, BPC-157 was administered at 10 mcg/kg in rodents, which does not translate linearly to human equivalents. Injection timing was typically once daily throughout the healing period.
Oral administration has been studied and shows efficacy in gut-specific models, though systemic effects via the oral route appear reduced.
This article is for research and educational purposes only. BPC-157 is not approved for human use by any regulatory authority.
Interested in the peptides discussed in this article?
Browse our full catalog of research-grade peptides or contact us for personalized recommendations.